• Amyloid Beta-Peptide (1-40) (human): Redefining Microglial M

  2026-06-04

  Explore the evolving role of Amyloid Beta-Peptide (1-40) (human) in Alzheimer’s disease research, focusing on its dualistic effects on neuroinflammation and practical assay optimization. This article provides new insights beyond conventional aggregation studies.

• PURPL lncRNA Modulates Senescence Reversal via H3K9me3 Pathw

  2026-06-04

  Wang et al. demonstrate that the long non-coding RNA PURPL acts as an epigenetic regulator of cellular senescence by modulating H3K9me3-mediated gene silencing. Their findings reveal that targeting PURPL can rejuvenate senescent cells, providing new avenues for anti-aging research and potential therapeutic interventions.

• Vasopressin Analogues as Multitasking Peptides: Focus on Lyp

  2026-06-03

  The referenced review systematically explores the biological diversity, therapeutic applications, and structural optimization of vasopressin analogues, highlighting lypressin acetate as a natural peptide with clinically relevant antidiuretic and vasoconstrictive properties. The study contextualizes peptide drug development challenges, advances in analog pharmacology, and emerging cross-domain uses, including antiviral research, offering researchers a technical foundation for translational and mechanistic studies.

• Lithium-Enhanced Exosomal Wnt10a Secretion Drives Osteogenes

  2026-06-03

  This study reveals how lithium augments bone mesenchymal stem cell (BMSC) osteogenesis by promoting Rab11a-mediated exosomal Wnt10a secretion and activating Wnt/β-catenin signaling. The findings clarify a mechanistic basis for lithium's role in bone regeneration and suggest new avenues for engineering stem cell-derived exosomes to enhance bone repair outcomes.

• Verbascoside: Precision PKC/NF-κB Inhibitor for Osteoclastog

  2026-06-02

  Verbascoside empowers osteoclastogenesis and PKC/NF-κB pathway research with reproducible, high-purity inhibition and robust workflow compatibility. Its data-backed potency and solubility profile make it indispensable for cell signaling and bone metabolism assays.

• Veratridine: Voltage-Gated Sodium Channel Opener in Research

  2026-06-02

  Veratridine is a benchmark voltage-gated sodium channel opener, enabling precise manipulation of sodium channel dynamics in both neuroscience and oncology research. This article delivers actionable workflows, troubleshooting know-how, and translational guidance for researchers aiming to maximize reproducibility and sensitivity in excitotoxicity and drug screening assays.

• Deferasirox Modulates Myeloid Differentiation via NF-κB and

  2026-06-01

  This recent study delineates how the iron chelator Deferasirox (Exjade) alters myeloid cell maturation by modulating NF-κB activity through mitochondrial ROS signaling. The findings provide mechanistic insight into Deferasirox’s hematopoietic effects in iron overload and myelodysplastic syndromes, highlighting stage-specific responses and transcriptional changes relevant for translational research.

• 4-Phenylbutyric Acid: Precision ER Stress Modulation in Rena

  2026-06-01

  Explore how 4-Phenylbutyric acid (4-PBA) advances ER stress pathway research, with a focus on renal models and new mechanistic insights. This article delivers an in-depth analysis of 4-PBA’s scientific applications and protocol optimization, setting it apart from existing guides.

• Ridaforolimus: Applied mTOR Inhibition in Cancer Cell Workfl

  2026-05-31

  Ridaforolimus (Deforolimus, MK-8669) stands out as a selective mTOR inhibitor for advanced cancer research, offering robust anti-proliferative and anti-angiogenic action at ultra-low nanomolar concentrations. This guide details actionable workflows, data-driven protocol tips, and troubleshooting strategies to maximize reproducibility and insight in apoptosis and senescence assays.

• Cathepsin B Inhibitor CA-074: Technical Guide and Protocols

  2026-05-30

  CA-074 is a nanomolar-potency, selective cathepsin B inhibitor designed for precise dissection of proteolytic pathways in cancer metastasis, neurotoxicity, and immune modulation. It is most applicable in in vitro and in vivo studies where selective inhibition of cathepsin B is critical, but should not be used where pan-cathepsin inhibition or long-term solution storage is required.

• FPR2/ALX Modulation Restricts Autoimmune Astrocytopathy via

  2026-05-29

  This study demonstrates that stimulation of the formyl peptide receptor 2 (FPR2/ALX) attenuates neuroinflammation in a mouse model of autoimmune astrocytopathy by modulating microglia and natural killer (NK) cell responses. The findings highlight the therapeutic potential of targeting FPR2/ALX for diseases like neuromyelitis optica spectrum disorder (NMOSD), where conventional treatments often fail to halt disease progression.

• Protoporphyrin IX: Applied Workflows for Photodynamic Assays

  2026-05-29

  Protoporphyrin IX stands at the crossroads of heme metabolism and innovative photodynamic applications, enabling precise cancer diagnostics and experimental ferroptosis modulation. This guide delivers actionable workflows, troubleshooting strategies, and the latest translational insights, empowering researchers to harness APExBIO’s high-purity Protoporphyrin IX for reproducible, cutting-edge results.

• JNK-IN-7: Selective JNK Inhibitor for Apoptosis & MAPK Assay

  2026-05-28

  JNK-IN-7 empowers precise dissection of JNK signaling in cell models of inflammation and apoptosis. Its covalent, nanomolar inhibition and pathway selectivity make it a cornerstone for MAPK pathway research and immune modulation workflows.

• Spiroplasma eriocheiris Entry Requires Clathrin-Mediated End

  2026-05-28

  This study reveals that Spiroplasma eriocheiris invades Drosophila S2 cells primarily via clathrin-mediated endocytosis and macropinocytosis, not through caveola-dependent pathways. The findings clarify cellular mechanisms underlying S. eriocheiris infection and offer a framework for future host-pathogen research in invertebrate models.

• Low-Affinity Blockade of N-Type Ca Channels by v-Agatoxin-IV

  2026-05-27

  Sidach and Mintz revisited the pharmacological profile of v-Agatoxin-IVA, revealing its low-affinity blockade of neuronal N-type calcium channels in addition to established P- and Q-type selectivity. Their findings refine channel classification and inform experimental strategies targeting calcium signaling in neurons.

15658 records 1/1044 page Next 12345 下5页 Last page